Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status.



We retrospectively investigated the medical records of 259 patients diagnosed with advanced NSCLC from January 2010 to August 2013, who were tested forEGFRmutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development (BM-OS) were evaluated and compared byEGFRmutational status.



Sixty-seven patients (25.9%) developed BM. Synchronous BM occurred more often in patients withEGFRmutation type (MT) (n = 20, 27.4%) compared withEGFRwild type (WT) (n = 27, 14.5%,p< 0.009). The median BM-OS was significantly longer in patients withEGFRMT than in those withEGFRWT (25.7 months vs. 3.8 months,p< 0.001), and a similar trend was noticed for patients with synchronous BM (25.7 months forEGFRMT vs. 6.8 months forEGFRWT,p< 0.001). However, in patients with metachronous BM development, the difference in BM-OS between patients withEGFRMT (14.6 months) andEGFRWT (2.5 months) did not reach statistical significance (p= 0.230).



Synchronous BM was more common in NSCLC patients withEGFRMT than in those withEGFRWT. However,EGFRmutations were associated with significantly longer median BM-OS, especially when the brain was the first metastatic site.
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Min Young
MY
Baek
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Hee Kyung
HK
Ahn
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Kyu Ree
KR
Park
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Hwa-Sun
HS
Park
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Shin Myung
SM
Kang
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Inkeun
I
Park
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Young Saing
YS
Kim
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Junshik
J
Hong
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Sun Jin
SJ
Sym
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Jinny
J
Park
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Jae Hoon
JH
Lee
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Dong Bok
DB
Shin
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Eun Kyung
EK
Cho
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000556:secondary*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012189:Retrospective Studies
D066246:ErbB Receptors
Brain metastases; Carcinoma, non-small-cell lung; Prognosis; Receptor, epidermal growth factor